CONCERT PHARMACEUTICLS INC Associate Director of Innovation …

The average salary for Associate Director of Innovation and Strategy at companies like CONCERT PHARMACEUTICLS INC in the United States is $203,200 as of August 27, 2024, …

CouponFollow Extension

$203200
OFF

CONCERT PHARMACEUTICLS INC Associate Director Of Innovation …

1 week from now

The average salary for Associate Director of Innovation and Strategy at companies like CONCERT PHARMACEUTICLS INC in the United States is $203,200 as of August 27, 2024, …

salary.com

$10
OFF

Concert Pharmaceuticals, Inc. Information - RocketReach

1 week from now

The Concert Pharmaceuticals, Inc. annual revenue was $10 million in 2024. How many people are employed at Concert Pharmaceuticals, Inc.? 48 people are ... Associate Director, CMC …

rocketreach.co

$213401
OFF

CONCERT PHARMACEUTICLS INC Director Of Consumer Insights …

1 week from now

The average salary for Director of Consumer Insights at companies like CONCERT PHARMACEUTICLS INC in the United States is $213,401 as of June 27, 2024, but the range …

salary.com

$213884
OFF

CONCERT PHARMACEUTICLS INC Inclusion Director Salary

1 week from now

The average salary for Inclusion Director at companies like CONCERT PHARMACEUTICLS INC in the United States is $213,884 as of August 27, 2024, but the range typically falls between …

salary.com

$32
OFF

Concert Pharmaceuticals Company Profile | Management And

1 week from now

Revenue. $32.6 M. Employees. 64. Founded. 2006. Funding History. Concert Pharmaceuticals raised a total of $278.5 M in funding over 7 rounds, and is a public traded company. Stock …

datanyze.com

$135500
OFF

Associate Director Jobs In New Jersey - Indeed

1 week from now

Associate Director, Device & Combination Product Method Development & Testing. Merck Sharp & Dohme. Rahway, NJ 07065. $135,500 - $213,400 a year. Full-time. The Associate Director …

indeed.com

FAQs about CONCERT PHARMACEUTICLS INC Associate Director of Innovation … Coupon?

What is Concert Pharmaceuticals?

Concert Pharmaceuticals is a late-stage biotechnology company. Sun Pharma, a drug major based in Mumbai, India, has completed the acquisition of this US-based company in a USD 576 million deal. Concert is pioneering the use of deuterium in medicinal chemistry. ...

How will Sun Pharma acquire concert?

Following the successful closing of the tender offer, Sun Pharma will acquire all remaining shares of Concert that are not tendered into the tender offer and all shares of Concert’s preferred stock through a second-step merger at the same price of $8.00 per share of common stock, plus one non-tradeable CVR. ...

Why did Sun Pharma buy concert ophthalmology & dermatology?

“Sun Pharma is building a global Dermatology and Ophthalmology franchise and aims to be a preferred development and commercial partner in these therapies worldwide. The acquisition of Concert adds a late-stage, potential best-in-class treatment for Alopecia Areata in deuruxolitinib,” said Abhay Gandhi, CEO North America, Sun Pharma. ...

Are Sun Pharma & concert liable for any forward-looking statements?

Unless required by law, each of Sun Pharma and Concert is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this communication, whether as a result of new information, future events or otherwise. The tender offer referenced in this document has not yet commenced. ...

Does concert have a patent portfolio?

Concert has an extensive patent portfolio, including its lead product candidate deuruxolitinib – an oral inhibitor of Janus kinases JAK1 and JAK2 for the treatment of Alopecia Areata, an autoimmune dermatological disease – which is in late-stage development. ...